Wire · operational-macro
MicuRx plans ADC licensing deal with ClearideBio worth up to USD 974 million in disclosed ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 13 October 2026 · Fusion42 review
Shanghai-based MicuRx Pharmaceutical plans to license its preclinical bispecific ADC MRX-23 to Switzerland's ClearideBio Therapeutics under agreements potentially worth up to USD 974 million in upfront and milestone payments. ClearideBio will gain exclusive worldwide rights for development and commercialization, with options to license up to six additional projects based on MicuRx's STOPIN ADC platform.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You face a major new commercial pathway in ADC biotechnology as licensing deals for preclinical assets now approach billion-dollar ceilings. This deal flags a strong market trend to shift early-stage ADC risk to emerging players like ClearideBio that may unlock new funding and partnership opportunities for your own platform technologies.
◆ Coverage
1 source · 13 Oct 2026
◆ Related on Wire
◆ Topics